CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 1,979 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,979 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58. Following the transaction, the chief technology officer owned 194,729 shares in the company, valued at approximately $4,677,390.58. The trade was a 1.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Trading Up 0.0%

NASDAQ:CBLL opened at $23.95 on Wednesday. The firm has a 50-day simple moving average of $19.77 and a 200-day simple moving average of $19.27. CeriBell, Inc. has a one year low of $10.85 and a one year high of $25.33. The firm has a market cap of $919.20 million, a P/E ratio of -13.61 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

CBLL has been the topic of a number of analyst reports. BTIG Research lifted their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Canaccord Genuity Group raised their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Barclays upgraded shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Finally, Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CBLL. Strs Ohio purchased a new stake in CeriBell in the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CeriBell in the 3rd quarter valued at approximately $33,000. CWM LLC boosted its stake in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares for about $307,000. Each filing stated that the shares were sold to cover tax-withholding obligations after equity awards vested, and the executives retained substantial remaining holdings. SEC insider transaction filings
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from zero shares on August 10, with a zero-day days-to-cover ratio. Because the figures include a “NaN” change and may reflect incomplete or anomalous reporting, they provide little actionable information about bearish positioning.
• Negative Sentiment: The cluster of sales by multiple senior executives could create a modest overhang for CBLL, particularly with the stock trading close to its 12-month peak. However, the relatively small size of the transactions and their stated tax-related purpose lessen the signal that management is broadly reducing exposure.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.